Advertisement

Blut

, Volume 61, Issue 2–3, pp 55–59 | Cite as

Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen

  • W. Stenzinger
  • A. Blömker
  • W. Hiddemann
  • J. van de Loo
Original article

Summary

Seventeen patients with advanced refractory multiple myeloma were treated with a 4-day continuous infusion of vincristine and adriamycin in combination with 4-day intermittent high-dose dexamethasone (VAD). Ten patients entered a partial remission (59%). Complete remission was not achieved in any patients. The median response duration was 11 months and the median survival of the responding patients was 18 months versus 5 months for non-responders. Major complications during VAD treatment were infections probably due to a combination of myelosuppression and intensive corticosteroid therapy. The VAD regimen offers a useful chemotherapy that produces an overall high response rate even in intensively pretreated patients resistant to first line therapy. The treatment results in a clear tendency to longer survival in responding patients.

Key words

Multiple myeloma Refractoriness Chemotherapy VAD regimen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexanian R, Barlogie B, Dixon D (1986) High-dose glucocorticoid treatment of resistant myeloma. Ann Int Med 105: 8–11Google Scholar
  2. 2.
    Alexanian R, Bonnet J, Gehan E, Haut A, Hewlett J, Lane M, Monto R, Wilson H (1972) Combination chemotherapy for multiple myeloma. Cancer 40: 2756–2771Google Scholar
  3. 3.
    Barlogie B, Alexanian R (1986) Therapy of primary resistant and relapsed multiple myeloma. Onkologie 9: 210–214Google Scholar
  4. 4.
    Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F (1988) Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 72: 2015–2019Google Scholar
  5. 5.
    Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl J Med 310: 1353–1356Google Scholar
  6. 6.
    Case DC, Lee BJ, Clarkson BD (1977) Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 63: 897–903Google Scholar
  7. 7.
    Cavo M, Galieni P, Tassi C, Gobbi M, Tura S (1988) M-2 protocol for melphalan-resistant and relapsing multiple myeloma. Eur J Haematol 40: 168–173Google Scholar
  8. 8.
    Collin R, Greaves M, Preston FE (1987) Potential value of vincristine-adriamycin-dexamethasone combination chemotherapy (VAD) in refractory and rapidly progressive myeloma. Eur J Haematol 39: 203–208Google Scholar
  9. 9.
    Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842–854Google Scholar
  10. 10.
    Durie BGM, Salmon SE (1982) The current status and future prospects of treatment for multiple myeloma. Clin Haematol 11: 181–210Google Scholar
  11. 11.
    Groupe d'Etudes et de Recherches sur le Myélome (GERM) (1986) Traitement des myélomes multiples résistant aux alkylants par vincristine-adriamycine en perfusion continue et dexaméthasone. Presse Méd 15: 2001–2004Google Scholar
  12. 12.
    Kaplan EL, Meier P (1958) Nonparametric estimate from incomplete observations. J Am Statist Assoc 53: 457–481Google Scholar
  13. 13.
    Lokhorst HM, Meuwissen OJAT, Bast EJEG, Dekker AW (1989) VAD chemotherapy for refractory multiple myeloma. Br J Haematol 71: 25–30Google Scholar
  14. 14.
    Mandelli F, Arrisati G, Petrucci MT, Amadori S, Boccadoro M, Gernone A, Lauta MV, Marmont F, Dammacco F, Tribalto M, Pileri A (1989) Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival durations of responding multiple myeloma patients (abstract). In: Barlogie B, Alexanian R (eds) Second international workshop on myeloma. Advances in biology and therapy. Houston, Texas, USA, pp 41–42Google Scholar
  15. 15.
    Palmer M, Belch A, Brox L, Pollock E, Koch M (1987) Are the current criteria for response useful in the management of multiple myeloma? J Clin Oncol 5: 1373–1377Google Scholar
  16. 16.
    Peest D, Schmoll HJ, Schedel J, Glück S, Schumacher K, Deicher H (1988) VBAMDex chemotherapy in advanced multiple myeloma. Eur J Haematol 40: 245–249Google Scholar
  17. 17.
    Pflüger KH, Görg K, Görg C, Havemann K (1987) Behandlung des multiplen Myeloms. Chemotherapie bei primärem und sekundärem Therapieversagen und bei Niereninsuffizienz. Med Klin 82: 16–22Google Scholar
  18. 18.
    Scheithauer W, Cortelezzi A, Kutzmits R, Baldini L, Ludwig H (1987) VAD protocol for treatment of advanced refractory multiple myeloma. Blut 55: 145–152Google Scholar
  19. 19.
    Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles R, Tillyer CR, Osborne RJ, Slevin ML, Malpas JS (1987) Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66: 55–62Google Scholar
  20. 20.
    Sheehan T, Judge M, Parker AC (1986) The efficacy and toxicity of VAD in the treatment of myeloma and related disorders. Scand J Haematol 37: 425–428Google Scholar
  21. 21.
    Sporn JR, McIntyre OR (1986) Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 13: 318–325Google Scholar
  22. 22.
    World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Geneva, WHO Publications, 38Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • W. Stenzinger
    • 1
  • A. Blömker
    • 1
  • W. Hiddemann
    • 1
  • J. van de Loo
    • 1
  1. 1.Department of Internal MedicineUniversity of MünsterMünsterFederal Republic of Germany

Personalised recommendations